The new findings show the Percepta Nasal Swab, a first-of-its-kind genomic test, accurately classifies lung cancer risk in current or former smokers with lung nodules so that those with benign nodules may safely avoid unnecessary additional procedures.
Read More
To identify and treat COVID-19 patients at an early stage, predictive biomarkers need to be identified; researchers have discovered one.
Read More
The study showed that the rapid liquid biopsy NGS test was able to accurately detect actionable genomic alterations in patients with NSCLC with a turnaround time of only 72 hours.
Read More
Guardant Health is joining forces with leading patient advocacy groups to expand the Clear Your View initiative to raise awareness of the important role complete biomarker testing plays in guiding initial treatment decisions for newly diagnosed advanced colorectal cancer patients.
Read More
The acquisition of Resolution Bioscience complements and expands Agilent’s capabilities in NGS-based cancer diagnostics.
Read More